Markets:

Overview

News

Currencies

International

Treasuries

iShares Biotechnology ETF (NQ:IBB)

169.96 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

What to Do Next With No Clear Stock Market Direction ↗

February 14, 2022

Monday can easily be a day that teaches us the importance of waiting from the sidelines for a better opportunity.

Via Talk Markets

Large Cap Biopharma- Well Positioned For Choppy Markets ↗

February 14, 2022

If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.

Via Talk Markets

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO ↗

February 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-...

Via Benzinga

The Dean Martin, “You’re Nobody ‘Till Somebody Loves You” Stock Market (And Sentiment Results)… ↗

February 11, 2022

China Tech (Alibaba) and Biotech have been the two least-loved sectors in recent weeks, but we believe this is changing.

Via Talk Markets

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Support and Resistance Levels to Watch for Thursday’s Trading Session ↗

February 09, 2022

Two of the major indices including the Russell 2000 and the Dow Jones have cleared key resistance levels, however, the S&P 500 and the Nasdaq 100 have yet to clear recent highs or major moving...

Via Talk Markets

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Is the Biotech Space Looking for a Major Price Move? ↗

February 08, 2022

The past four trading days have held roughly the same price areas within the major indices.

Via Talk Markets

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures ↗

February 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗

February 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Transportation Gets Boosted While Retail Fumbles ↗

February 02, 2022

If IYT can hold over its major moving averages, watch for XRT to clear its current trading range and hold over $83.29 before looking for the next push upwards.

Via Talk Markets

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗

February 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

3 Key Price Levels The Nasdaq 100, Russell 2000, and Bitcoin Need to Clear ↗

February 01, 2022

The market is holding its current trading area and though we are at a pivotal point, Wednesday could have another push higher if key levels are cleared.

Via Talk Markets

CNBC's Final Trades: NXP Semiconductors, Qualcomm, Deere And This Way To Gain Exposure To Growth Potential ↗

February 01, 2022

On CNBC’s “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners named NXP Semiconductors NV (NASDAQ: NXPI) as his pick, noting that the company is scheduled to rep

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗

February 01, 2022

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Small Cap Biotech Stocks: Is it time to start trading? ↗

January 31, 2022

It’s time to trade beaten-up small cap biotech stocks.

Via Talk Markets

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

Weekly Commentary: The High-Wire Act Has Commenced ↗

January 30, 2022

Geez. I guess it’s been a long time since we’ve experienced a hawkish central banker. Powell needed to talk tough on inflation. Yet he seemed determined to occupy the middle ground. There was no...

Via Talk Markets

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study ↗

January 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Key Price Levels to Watch in the Current Choppy Market ↗

January 26, 2022

Because Monday had such a significant breakdown paired with an end-of-day rally it gave us a temporary support level to watch.

Via Talk Markets

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data ↗

January 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Major Indices Set a Key Support Level as Commodities Heat Up ↗

January 25, 2022

The market is looking to hold its current price area along with Monday’s low as a new key support level.

Via Talk Markets

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data ↗

January 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...

Via Benzinga

Watch These Two Symbols as Indictors for a Continued Market Rally ↗

January 24, 2022

If we are looking for the market to continue higher, JNK should hold over $106.48 and VXX should not clear its 200-DMA at $27.99.

Via Talk Markets

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

iShares Biotechnology ETF (NQ:IBB)

All News about iShares Biotechnology ETF

Starting at $3.75/week.

Subscribe Today